Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on October 21st, 2016 by Betsy DavisPharma R&D
Small new companies, often simply called “start-ups,” have become the heart of innovation in the pharmaceutical industry, and it’s easy to forget that wasn’t a predictable development. Continue reading “Lights up on Innovation: Start-up Spotlight” »
Posted on October 20th, 2016 by Christy J. WilsonPharma R&D
When Elsevier R&D Solutions launched its new initiative, dubbed The Hive, earlier this year, its aim was to identify a handful of bright biotech start-ups to participate in a collaborative effort designed to boost early stage drug discovery and development. Continue reading “New Hive Participants Tackle Unmet Needs” »
Posted on October 20th, 2016 by Betsy DavisPharma R&D
Drug discovery and development was once a very secretive process where the major industry players were intent on keeping their research to themselves in order to stay competitive.
Posted on October 19th, 2016 by Dr. Makarand Jawadekar, Ph.DPharma R&D
For years, the pharmaceutical or biopharma industry and the information technology (IT) sector seemed to be more or less separate entities. This has certainly changed in more recent times. Continue reading “The Intersection of Pharma and Tech: Digital Pharma” »
Posted on October 17th, 2016 by Thibault GeouiChemistry
What matters the most to scientific researchers? While there may be many answers to that question, one that stands out is the ability to better humanity through scientific discovery. Continue reading “Getting to Chemistry Breakthroughs Faster” »
Posted on October 14th, 2016 by Patrick C. May, PH.D.Pharma R&D
Many an undergrad biochemistry student is challenged to remember the difference between the amino acids valine and isoleucine. They differ by a single methyl group in their side chains Continue reading “A Small Change with Big Implications for Alzheimer’s Research” »
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.